Clinical Trials Logo

Clinical Trial Summary

Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its prognosis is extremely poor. Previous studies indicate that both bevacizumab and PD-1 inhibitor have clinical benefits for OCCC patients. And the combination of bevacizumab and PD-1 inhibitor has shown preliminary safety and clinical activity. Therefore, this study aims to investigate the potential benefit of combination therapy for patients with OCCC.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04735861
Study type Interventional
Source Tongji Hospital
Contact Qinglei Gao, PhD, MD
Phone +86-13871127473
Email qingleigao@hotmail.com
Status Recruiting
Phase Phase 2
Start date April 7, 2021
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT05296512 - Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer Phase 2
Completed NCT01914510 - A Study of ENMD-2076 in Ovarian Clear Cell Cancers Phase 2
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Recruiting NCT03405454 - A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Phase 2
Not yet recruiting NCT05600998 - A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma N/A
Recruiting NCT06065462 - Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 Phase 1/Phase 2
Recruiting NCT05099978 - Asian Multicenter Prospective Study of ctDNA Sequencing
Not yet recruiting NCT05759312 - Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma Phase 1/Phase 2
Not yet recruiting NCT06279104 - A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Terminated NCT02837991 - A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Phase 1
Recruiting NCT05498597 - AMT-151 in Patients With Selected Advanced Solid Tumours Phase 1
Recruiting NCT05226507 - A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer Phase 1
Recruiting NCT05281471 - Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) Phase 3
Recruiting NCT02866370 - Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Phase 2